Page 337 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.14. Treatment characteristics—changes in treatment patterns over time (continued)
Author Database Treatment 1980- 1985-89 1990-94 1995- 2000-04 2005- Statistical Notes
Year 84 99 10 analysis
PMID
CaPSURE AS/WW P=0.46 A trend line for
(intermediate (Mantel-Haenszel the frequency
risk) test for trend) of undergoing
WW is
presented in
the single
Figure of the
paper.
CaPSURE AS/WW P=0.14 A trend line for
(high risk) (Mantel-Haenszel the frequency
test for trend) of undergoing
WW is
presented in
the single
Figure of the
paper.
67
Cooperberg CaPSURE WW 13.8% 12.5% 7.9% P for trend Low-risk
2004 ADT 3.1% 12.8% 12.0% <0.001 for all Tx prostate
15169800 EBRT 16.1% 8.9% 6.8% except RP; cancer
BT 5.1% 8.9% 21.7% P=0.0019 for RP. patients only
RP 63.8% 56.9% 51.6% (n=1990)
(1989-92) (1996- (1999-
98) 2001)
90
Cooperberg CaPSURE WW 4.4% 3.9% 2.7% 3.0% P<0.001 High risk
2008 ADT 18.5% 22.6% 26.4% 29.1% (Cuzick test for localized
18369637 EBRT 21.6% 14.6% 12.3% 10.9% trend) prostate
BT 4.3% 11.6% 13.4% 6.6% cancer only
Cryotherapy 6.2% 4.1% 4.8% 8.5%
RP 45% 43.2% 40.5% 41.9%
(1990-94) (1995- (2002-03) (2004-
99) 07)
69
Cooperberg CaPSURE AS/WW 12.8% 7.1% 7.2% 8.5% NR
2010 (CAPRA 0-2) RP 61.6% 61.6% 59.6% 59.5%
20124165 RT 14.1% 22.8% 23.2% 20.9%
ADT 4.7% 6.3% 7.1% 6.4%
(1990-94) (1995- (2002-03) (2004-
99) 07)

C-86